International Clinical Trial: A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT06703606) titled 'A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A' on Nov. 21, 2024.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Pfizer

Condition: Severe Hemophilia A

Intervention: Drug: MARSTACIMAB

Recruitment Status: Recruiting

Phase: Phase 1

Date of First Enrollment: May 13, 2025

Target Sample Size: 15

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/ct2/show/NCT067036...